Alpha Profiles · Company Profile

Mineralys Therapeutics, Inc.

Canonical company identity and public leadership record.

https://registry.alpha.ac/companies/mineralys-therapeutics-inc

Entity: Public listing published
Primary listing: NASDAQ: MLYS
Verification: Partially verified
Last reviewed: 2026-09-12T21:31:19.628491+00:00

Overview

Alpha's canonical identity and public leadership record for Mineralys Therapeutics, Inc..

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

7 public records

Adam Levy

Chief Financial Officer and Secretary

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001933414-26-000069Apr 8, 2026

Anton J. Levy

Chief Financial Officer and Secretary

State: confirmed
Effective: From Mar 12, 2026
Confidence: 94%
Evidence: MLYS 10-K executive officersMar 12, 2026

David Rodman

Chief Medical Officer

State: confirmed
Effective: From Mar 12, 2026
Confidence: 94%
Evidence: MLYS 10-K executive officersMar 12, 2026

David Rodman, M.D.

Chief Medical Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001933414-26-000069Apr 8, 2026

Eric Warren

Chief Commercial Officer

State: confirmed
Effective: From Mar 12, 2026
Confidence: 94%
Evidence: MLYS 10-K executive officersMar 12, 2026

Eric Warren, R.Ph.

Chief Commercial Officer

State: confirmed
Effective: Date not stated
Confidence: 94%
Evidence: MLYS executive roster sourceMay 3, 2026

Jon Congleton

President and Chief Executive Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001933414-26-000069Apr 8, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 12, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.